Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 8. ATRX and TILs on the TMA of BC. Representative images for ATRX low (A) and ATRX high (B) in the samples. Representative images for TILs low (C) and TILs high (D) in the samples. The images of (A, C) came from the same sample, while the ones of (B, D) came from another sample. (E) Statistical analysis of ATRX expression. (F) Univariate analysis screened risk factors for OS in patients with BC.